Lymphoid Cancer Research

What We Do

Our main research focus is to improve patient outcomes by gaining deeper understanding of lymphoma biology and disease progression which can be translated into clinical applications. Our ultimate goal is to improve patient outcomes through enhanced precision medicine, which can be designed using advanced genomic tools.

News & Events

Dr. David Scott named to Lymphoma Research Foundation scientific advisory board

The Lymphoma Research Foundation (LRF) is the largest non-profit lymphoma research organization in North America with a volunteer scientific advisory board comprised of world-renowned lymphoma experts, including Dr. David Scott. Dr. Scott is the clinical director of the BC Cancer Centre for Lymphoid Cancer, deputy head of the BC Cancer Lymphoid Cancer Research and an associate professor at the University of British Columbia. Dr.

More Info about Dr. David Scott named to Lymphoma Research Foundation scientific advisory board

BC Cancer researchers uncover therapeutically exploitable gene mutation in B-cell lymphoma

This understanding may be applicable to other cancer types in the future.

More Info about BC Cancer researchers uncover therapeutically exploitable gene mutation in B-cell lymphoma

Dr. Christian Steidl receives the Allen Distinguished Investigator Award

The research director of the Centre for Lymphoid Cancer at BC Cancer is the first Canadian recipient.

More Info about Dr. Christian Steidl receives the Allen Distinguished Investigator Award

New discovery reveals how Hodgkin lymphoma avoids attack from immune cells

BC Cancer researchers with the Centre for Lymphoid Cancer have discovered key information about how Hodgkin lymphoma can grow undetected within the body.

More Info about New discovery reveals how Hodgkin lymphoma avoids attack from immune cells

View all news

Research Labs & Principal Investigators

Scott Lab

Steidl Lab

Venturutti Lab

Recent Publications

Mutant EZH2 Induces a Pre-malignant Lymphoma Niche by Reprogramming the Immune Response

Cancer Cell, 2020

Béguelin W, Teater M, Meydan C, Hoehn KB, Phillip JM, Soshnev AA, Venturutti L, Rivas MA, Calvo-Fernández MT, Gutierrez J, Camarillo JM, Takata K, Tarte K, Kelleher NL, Steidl C, Mason CE, Elemento O, Allis CD, Kleinstein SH, Melnick AM

Learn More

Characterization of DLBCL with a PMBL gene expression signature

Blood

Duns G, Viganò E, Ennishi D, Sarkozy C, Hung SS, Chavez EA, Takata K, Rushton C, Jiang A, Ben-Neriah S, Woolcock B, Slack GW, Hsi ED, Craig JW, Hilton LK, Shah S, Farinha P, Mottok A, Gascoyne RD, Morin RD, Savage KJ, Scott DW, Steidl C.

Learn More

Impact of MYC and BCL2 structural variants in tumors of DLBCL morphology and mechanisms of false-negative MYC IHC

Blood

Collinge B, Ben-Neriah S, Chong L, Boyle M, Jiang A, Takata T, Farinha P, Craig JW, Slack GW, Ennishi D, Mottok A, Meissner B, Chavez E, Gerrie AS, Villa D, Freeman C, Savage KJ, Sehn LH, Morin RD, Mungall AJ, Gascoyne RD, Marra MA, Connors JM, Steidl C and Scott DW

Learn More